Allergan's third-quarter revenues rose by 3.6 percent to $4,051 million. The group posted an operating loss of $596.6 million for the period compared with an operating profit of $257.7 million a year earlier. On an adjusted basis, it booked operating income of $1,760 million, down by 7.7 percent. Allergan increased its guidance for this year's revenues to $15,625-15,825 million.